You are here
Iron Man: Novel Technologies for Autonomous Defense
Award Information
Agency: Department of Defense
Branch: Defense Advanced Research Projects Agency
Contract: W911NF-09-C-0162
Agency Tracking Number: A09A-013-0259
Amount:
$100,000.00
Phase:
Phase I
Program:
STTR
Solicitation Topic Code:
A09A-T013
Solicitation Number:
2009.A
Timeline
Solicitation Year:
2009
Award Year:
2009
Award Start Date (Proposal Award Date):
2009-09-22
Award End Date (Contract End Date):
2010-03-21
Small Business Information
278 DP Road, Suite D
Los Alamos, NM
87544
United States
DUNS:
147452275
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: Eva Birnbaum
Title: CSO
Phone: (505) 412-2345
Email: eva@cpsci.com
Title: CSO
Phone: (505) 412-2345
Email: eva@cpsci.com
Business Contact
Name: Benjamin Warner
Title: CEO
Phone: (505) 412-2345
Email: warner@cpsci.com
Title: CEO
Phone: (505) 412-2345
Email: warner@cpsci.com
Research Institution
Name: Harvard Medical School
Contact: Nicole Touchet
Address:
Phone: (617) 417-9622
Type: Nonprofit College or University
Contact: Nicole Touchet
Address:
25 Shattuck Street
Boston, MA
2115
United States
Phone: (617) 417-9622
Type: Nonprofit College or University
Abstract
Caldera Pharmaceuticals proposes to develop a highly metal-selective system to maintain iron concentrations in the body at optimal levels to prevent infections. The system will control iron without the loss of other essential micronutrients; loss of micronutrients is the cause of toxicity in most chelation systems. Metal selectivity and the corresponding safety for use is the key difference between Caldera’s system and other therapies. Caldera’s XRpro® will be used to conduct discovery-phase steps. Harvard collaborators will help to design and conduct a human study to determine whether optimal iron levels decrease spontaneous infection rates in a healthy population.
* Information listed above is at the time of submission. *